Ciclopirox nail lacquer and podiatric practice

Journal of the American Podiatric Medical Association

Volumn 90, Issue 10, 2000, Pages 502-507

  Gupta, Aditya K ^a,b   Malkin, Kenneth F ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b American College of Podiatric Medical Review ^*

^c American College of Podiatric Medical Review   (United States)

^d American Board of Podiatric Orthopedics and Primary Podiatric Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROX; PYRIDONE DERIVATIVE;

AGED; ARTICLE; DEBRIDEMENT; HISTORY; HUMAN; ONYCHOMYCOSIS; PODIATRY; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, TOPICAL; AGED; ANTIFUNGAL AGENTS; DEBRIDEMENT; FOOT DERMATOSES; HISTORY, 20TH CENTURY; HUMANS; ONYCHOMYCOSIS; PODIATRY; PYRIDONES; UNITED STATES;

EID: 0034330772     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-90-10-502     Document Type: Article

References (32)

1. US BUREAU OF THE CENSUS: Population Profile of the United States: 1997, Current Population Reports, US Government Printing Office, Washington, DC, 1998.
2. GUPTA AK, JAIN HC, LYNDE CW, ET AL: Prevalence of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada: a multicenter survey of 2001 patients. Int J Dermatol 36: 783, 1997.
3. BEAUREGARD S, GILCHREST BA: A survey of skin problems and skin care regimens in the elderly. Arch Dermatol 123: 1638, 1987.
4. HOOI JD, STOFFERS HE, KNOTTNERUS JA, ET AL: The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence. Br J Gen Pract 49: 49, 1999.
5. KENNY SJ, AUBERT RE, GEISS LS: "Prevalence and Incidence of Non-Insulin-Dependent Diabetes," in Diabetes in America, 2nd Ed, ed by MI Harris, p 47, US Department of Health and Human Services, Bethesda, MD, 1995.
6. GUPTA AK, KONNIKOV N, MACDONALD P, ET AL: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 139: 665, 1998.
7. BOYNKO WL, DOYLE JJ, RYU S, ET AL: Onychomycosis and its impact on secondary infection development in the diabetic population [poster]. Presented at the Fourth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 23-26, 1999, Arlington, VA.
8. REIBER GE, BOYKO EJ, SMITH DG: "Lower Extremity Foot Ulcers and Amputations in Diabetics," in Diabetes in America, 2nd Ed, ed by MI Harris, p 409, US Department of Health and Human Services, Bethesda, MD, 1995.
9. SOWELL RD, MANGEL WB, KILCZEWSKI CJ, ET AL: Effect of podiatric medical care on rates of lower-extremity amputation in a Medicare population. JAPMA 89: 312, 1999.
10. VAN GILS CC, WHEELER LA, MELLSTROM M, ET AL: Amputation prevention by vascular surgery and podiatry collaboration in high-risk diabetic and nondiabetic patients: the Operation Desert Foot experience. Diabetes Care 22: 678, 1999.
11. BOULTON AJ: Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med 15 (suppl 4): S57, 1998.
12. RONNEMAA T, HAMALAINEN H, TOIKKA T, ET AL: Evaluation of the impact of podiatrist care in the primary prevention of foot problems in diabetic subjects. Diabetes Care 20: 1833, 1997.
13. LITZELMAN DK, SLEMENDA CW, LANGEFELD CD, ET AL: Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus: a randomized, controlled trial. Ann Intern Med 119: 36, 1993.
14. DRAKE LA, PATRICK DL, FLECKMAN P, ET AL: The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 41: 189, 1999.
15. GUFTA AK, SAUDER DN, SHEAR NH: Antifungal agents: an overview. part I. J Am Acad Dermatol 30: 677, 1994.
16. GUPTA AK, SAUDER DN, SHEAR NH: Antifungal agents: an overview. part H. J Am Acad Dermatol 30: 911, 1994.
17. GUPTA AK, SHEAR NH: The new oral antifungal agents for onychomycosis of the toenails: a review. J Eur Acad Dermatol Venereol 13: 1, 1999.
18. GUPTA AK, SHEAR NH: An update, with a risk-benefit evaluation of the newer oral antifungal agents to treat onychomycosis. Drug Saf 22: 33, 2000.
19. NIEWERTH M, KORTING H: The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 10: 155, 2000.
20. PETERSEN EA, ALLING DW, KILPATRICK CH: Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med 93: 791, 1980.
21. HORSBURGH CR JR, KIRKPATRICK CH: Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 74: 23, 1983.
22. TKACH JR, RINALDI MG: Severe hepatitis associated with ketoconazole therapy for chronic mucocutaneous candidiasis. Cutis 29: 482, 1982.
23. KNIGHT TE, SHIKUMA CY, KNIGHT J: Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 25 (2 pt 2): 398, 1991.
24. BERNUAU J, DURAND F, PESSAYRE D: Ketoconazole-induced hepatotoxicity. Hepatology 26: 802, 1997.
25. CHIEN RN, YANG LJ, LIN PY, ET AL: Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 25: 103, 1997.
26. GARCIA RODRIGUEZ LA, DUQUE A, CASTELLSAGUE J, ET AL: A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48: 847, 1999.
27. CLISSOLD SP: "Safety in Clinical Practice," in Ketoconazole Today: A Review of Clinical Experience, ed by HE Jones, p 77, ADIS Press, Manchester, England, 1987.
28. Physicians' Desk Reference, 53rd Ed, p 1428, Medical Economics Co, Montvale, NJ, 1999.
29. Physicians' Desk Reference, 53rd Ed, p 1436, Medical Economics Co, Montvale, NJ, 1999.
30. Physicians' Desk Reference, 53rd Ed, p 2038, Medical Economics Co, Montvale, NJ, 1999.
31. Penlac (ciclopirox) nail lacquer Topical Solution, 8% [package insert], Dermik Laboratories, Inc, Collegeville, PA, December 1999.
32. Dorland's Illustrated Medical Dictionary, 29th Ed, sv "debridement," WB Saunders, Philadelphia, 2000.